Here’s whether AstraZeneca PLC (AZN) is worth buying in 2026 —
based on weekly-updated price trend, RSI momentum, and return vs.
the S&P 500. Our current read: Neutral.
🔵
Neutral
Positives: trading above the 200-day MA (long-term uptrend intact); RSI 39 — healthy momentum range; strong 1-year return of +138.3%. Concerns: below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-0.91% over 10 days); 3-month momentum negative (-6.9%). Currently 16.0% off its 52-week high. Score: +1/7.
AZN is holding above its long-term 200-day MA ($135.24) but has slipped below the 50-day MA ($189.14), pointing to short-term weakness in an otherwise intact trend. An RSI of 39.4 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +138.3% compares to +22.9% for SPY (beat the market by 115.5%).
$10,000 invested 1 year ago→ $23,833 today
vs. S&P 500 (SPY) — same period beat market by 115.5%
1-Year Price Chart
Daily candles
MA-50MA-200UpDown
Signal Check
✓Above 200-day MA ($135.24)
✗Above 50-day MA ($189.14)
✓RSI(14) neutral zone (30–70) — currently 39.4
✓Positive return (+138.3%)
!Within 10% of period high (−16.0%)
Period Range $178.75
$68.62$212.71
RSI (14) 39.4
0 · OversoldOverbought · 100
Key Metrics
Price$178.75
Period Return+138.3%
Period High$212.71
Period Low$68.62
Drawdown−16.0%
MA-50$189.14
MA-200$135.24
RSI (14)39.4
Avg Volume (30d)1.9M
vs. SPYbeat by 115.5%
Return Rank#138 of 1246
Trend Signals
Price is above the 200-day moving average ($135.24)
Price is below the 50-day moving average ($189.14)